La cadena de opciones muestra datos clave de las opciones de acciones de BriaCell Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para BriaCell Therapeutics..

BriaCell Therapeutics (NASDAQ:BCTX) Bolsa, Cadena de Opciones

BriaCell Therapeutics

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Pre-Market Outlook

Markets

Movers

ACON

AEON

BCTX

CPHC

EKSO

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

KITT

LDTC

MBOT

MEGL

MNSO

NSTS

SPPL

WFCF

Explora los mayores movimientos en el premercado con ganancias superiores al 100% y pérdidas significativas antes de la apertura.

Acciones de Smart Share Global se disparan un 44%; 20 acciones que se mueven en el premercado

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics Corp

News

Financing

Press Releases

BriaCell Therapeutics Announces Closing of $15 million Public Offering

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Legal

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

BriaCell Awarded $2 Million NCI Grant to Advance  Bria-PROS+™ in Prostate Cancer

Analyst Ratings

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

BCTXW

BCTXZ

TSX:BCT

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

BioCardia

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

ESSA Pharma

Evogene

HCW Biologics

iBio

Imunon

IN8bio

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Leap Therapeutics

Mustang Bio

Marker Therapeutics

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

HC Wainwright & Co.

Comments

BriaCell Therapeutics

BriaCell Therapeutics (BCTX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL